Stock listing
NASDAQ:MPLT MapLight Therapeutics, Inc. Stock
Home listing (NASDAQ) of MapLight Therapeutics, Inc.
Follow MapLight Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:MPLT
$5.94 USD -0.71 (-10.7%)
Close on Nov 20, 2026
- Day range
- $5.93 – $6.48 USDNov 20, 2026
- Volume
- 357,935 sharesNov 20, 2026
- Market cap
- $313.9M USDAt the close on Nov 20, 2026 · price × 52.85M shares outstanding
- 52-week range
- $5.93 – $40.43 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $4.67M USDMedian day 411,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:MPLT · Home | $5.94 USD | -0.71 (-10.7%) | 357,935 | $6.33 | $6.48 | $5.93 | $6.65 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MPLT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $5.94 | -0.71 | -10.7% | $6.33 | $6.48 | $5.93 | 357,935 | |
| $6.65 | +0.08 | +1.2% | $6.50 | $6.86 | $6.43 | 416,883 | |
| $6.57 | -0.33 | -4.8% | $6.87 | $6.91 | $6.42 | 547,765 | |
| $6.90 | -0.35 | -4.8% | $7.33 | $7.48 | $6.88 | 305,244 | |
| $7.25 | +0.18 | +2.5% | $7.10 | $7.376 | $6.95 | 367,746 | |
| $7.07 | -0.41 | -5.5% | $7.46 | $7.635 | $7.01 | 266,219 | |
| $7.48 | +0.04 | +0.5% | $7.48 | $7.80 | $7.41 | 291,886 | |
| $7.44 | +0.16 | +2.2% | $7.25 | $7.68 | $7.23 | 460,517 | |
| $7.28 | +0.35 | +5.1% | $7.11 | $7.62 | $6.86 | 458,792 | |
| $6.93 | +0.71 | +11.4% | $6.24 | $6.93 | $6.06 | 492,056 | |
| $6.22 | -0.49 | -7.3% | $6.67 | $6.71 | $6.20 | 442,663 | |
| $6.71 | -0.10 | -1.5% | $6.80 | $7.14 | $6.50 | 388,883 | |
| $6.81 | +0.03 | +0.4% | $6.82 | $7.15 | $6.80 | 345,175 | |
| $6.78 | -0.80 | -10.6% | $7.65 | $7.665 | $6.765 | 245,490 | |
| $7.58 | -0.14 | -1.8% | $7.70 | $7.81 | $7.44 | 394,984 | |
| $7.72 | -0.26 | -3.3% | $8.08 | $8.192 | $7.65 | 156,676 | |
| $7.98 | -0.19 | -2.3% | $8.09 | $8.135 | $7.81 | 365,932 | |
| $8.17 | +0.51 | +6.7% | $7.66 | $8.25 | $7.50 | 384,829 | |
| $7.66 | -0.31 | -3.9% | $7.98 | $8.34 | $7.58 | 252,481 | |
| $7.97 | -0.28 | -3.4% | $8.18 | $8.285 | $7.84 | 305,300 | |
| $8.25 | +0.09 | +1.1% | $8.16 | $8.485 | $7.96 | 349,500 | |
| $8.16 | -0.08 | -1.0% | $8.21 | $8.58 | $7.995 | 343,800 | |
| $8.24 | +0.24 | +3.0% | $8.33 | $8.55 | $8.03 | 355,000 | |
| $8.00 | +0.30 | +3.9% | $7.73 | $8.07 | $7.66 | 278,700 | |
| $7.70 | -0.32 | -4.0% | $8.10 | $8.10 | $7.56 | 359,100 | |
| $8.02 | +0.21 | +2.7% | $7.84 | $8.43 | $7.743 | 658,400 | |
| $7.81 | -0.065 | -0.8% | $7.78 | $8.075 | $7.46 | 450,900 | |
| $7.875 | -0.725 | -8.4% | $8.60 | $8.60 | $7.85 | 301,700 | |
| $8.60 | -0.23 | -2.6% | $8.82 | $8.90 | $8.48 | 485,200 | |
| $8.83 | -0.32 | -3.5% | $9.15 | $9.415 | $8.70 | 495,400 | |
| $9.15 | -0.21 | -2.2% | $9.30 | $9.33 | $9.00 | 217,600 | |
| $9.36 | -0.33 | -3.4% | $9.62 | $9.88 | $9.30 | 275,200 | |
| $9.69 | +0.415 | +4.5% | $9.24 | $9.97 | $8.92 | 495,600 | |
| $9.275 | -0.545 | -5.5% | $9.80 | $9.80 | $9.19 | 262,000 | |
| $9.82 | +0.19 | +2.0% | $9.70 | $10.17 | $9.43 | 565,700 | |
| $9.63 | -0.56 | -5.5% | $10.16 | $10.17 | $9.57 | 432,200 | |
| $10.19 | +0.04 | +0.4% | $10.45 | $10.51 | $9.93 | 303,300 | |
| $10.15 | -0.30 | -2.9% | $10.64 | $10.64 | $10.12 | 408,300 | |
| $10.45 | -0.01 | -0.1% | $10.39 | $10.59 | $10.15 | 251,600 | |
| $10.46 | -0.30 | -2.8% | $10.81 | $10.87 | $10.39 | 317,500 | |
| $10.76 | -0.01 | -0.1% | $10.60 | $10.86 | $10.16 | 341,800 | |
| $10.77 | -0.09 | -0.8% | $10.89 | $10.93 | $10.13 | 539,000 | |
| $10.86 | -0.04 | -0.4% | $11.02 | $11.28 | $10.64 | 411,300 | |
| $10.90 | -0.02 | -0.2% | $11.06 | $11.28 | $10.78 | 542,900 | |
| $10.92 | -0.40 | -3.5% | $11.21 | $11.21 | $10.51 | 1,832,900 | |
| $11.32 | -0.08 | -0.7% | $11.57 | $11.73 | $11.13 | 545,900 | |
| $11.40 | -0.68 | -5.6% | $12.06 | $12.16 | $11.35 | 613,900 | |
| $12.08 | -1.07 | -8.1% | $13.10 | $13.11 | $12.05 | 402,300 | |
| $13.15 | +0.15 | +1.2% | $13.08 | $13.45 | $12.66 | 327,600 | |
| $13.00 | -0.785 | -5.7% | $13.88 | $14.14 | $12.80 | 340,200 | |
| $13.79 | +0.075 | +0.5% | $13.49 | $14.04 | $13.19 | 490,300 | |
| $13.71 | -0.24 | -1.7% | $13.95 | $14.22 | $13.51 | 500,200 | |
| $13.95 | +0.18 | +1.3% | $13.49 | $14.09 | $13.19 | 522,000 | |
| $13.77 | +0.63 | +4.8% | $13.03 | $14.14 | $13.00 | 550,900 | |
| $13.14 | +0.08 | +0.6% | $13.20 | $13.45 | $12.96 | 863,500 | |
| $13.06 | -0.25 | -1.9% | $13.33 | $13.94 | $12.82 | 937,700 | |
| $13.31 | +0.34 | +2.6% | $12.99 | $13.93 | $12.32 | 580,700 | |
| $12.97 | +0.37 | +2.9% | $12.59 | $13.07 | $12.12 | 440,600 | |
| $12.60 | +0.06 | +0.5% | $12.65 | $12.84 | $12.20 | 375,100 | |
| $12.54 | -0.32 | -2.5% | $12.87 | $13.24 | $12.50 | 741,500 | |
| $12.86 | +0.32 | +2.6% | $12.47 | $12.95 | $11.71 | 910,000 | |
| $12.54 | +1.18 | +10.4% | $11.47 | $12.74 | $11.35 | 703,481 | |
| $11.36 | +0.15 | +1.3% | $11.21 | $11.44 | $10.51 | 563,455 | |
| $11.21 | -0.02 | -0.2% | $11.35 | $11.61 | $11.07 | 435,400 | |
| $11.23 | -0.92 | -7.6% | $12.07 | $12.21 | $10.96 | 555,300 |
- Ticker
- NASDAQ:MPLT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Latest deck · Nov 16, 2026
Investor Presentation (November 2026)
Investor deck · 28 slides
Latest news
MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 16, 2026
Closed $6.90 (-4.8%) on Nov 16, 2026
MapLight Therapeutics to Participate in Upcoming Investor Conference
Nov 9, 2026
Closed $7.44 (+2.2%) on Nov 10, 2026
MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics
Oct 6, 2026
Closed $9.69 (+4.5%) on Oct 6, 2026
MapLight Therapeutics Announces $150 Million Private Placement Financing
Aug 13, 2026
Closed $11.58 (+1.8%) on Aug 13, 2026
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
Jul 27, 2026
Closed $9.91 (-72.9%) on Jul 27, 2026
MapLight Therapeutics Announces Changes to Board of Directors
Jun 24, 2026
Closed $30.65 (+7.0%) on Jun 24, 2026
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
Jun 22, 2026
Closed $29.79 (+3.4%) on Jun 22, 2026
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
Closed $28.73 (-1.9%) on May 15, 2026
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
May 1, 2026
Closed $30.70 (-3.7%) on May 1, 2026
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Mar 26, 2026
Closed $19.23 (+6.0%) on Mar 26, 2026
MapLight Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 18 in all · newest Nov 16, 2026 · oldest 2025
- Decks
- 8 decks · latest Nov 16, 2026
Where MapLight Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:MPLT · Home listing · This page | NASDAQ | United States | USD |
| BOATS:MPLT | BOATS | United States | USD |
Valuation
Price/book 0.7× against a median of 2.5×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $29.84M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.28
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| MapLight Therapeutics, Inc. · NASDAQ:MPLT | US$313.9M | US$29.84M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 1.28 |
| Lyell Immunopharma, Inc. · NASDAQ:LYEL | US$339.3M | US$196.5M | n/a | 13,099× | n/a | 1.8× | n/a | 0.2× | 1.51 |
| Avacta Group PLC · LSE:AVCT | US$337.8M | US$337.2M | n/a | 2,281× | n/a | 68.5× | n/a | 5.3× | n/a |
| Inovio Pharmaceuticals, Inc. · NASDAQ:INO | US$329.7M | US$7.56B | n/a | 25,303× | 3.4× | n/a | n/a | n/a | 0.70 |
| Larimar Therapeutics, Inc. · NASDAQ:LRMR | US$328.6M | US$204.7M | n/a | n/a | n/a | 3.2× | n/a | 0.1× | 1.48 |
| CytoDyn Inc. · OTC:CYDY | US$326.4M | US$345.8M | n/a | n/a | n/a | n/a | n/a | n/a | 0.44 |
| C4 Therapeutics, Inc. · NASDAQ:CCCC | US$325.7M | US$175.5M | n/a | 5.4× | n/a | 1.4× | −282.2% | 0.2× | 1.46 |
| Laekna, Inc. · HKEX:2105 | US$322.8M | US$154.7M | n/a | 9.7× | n/a | 1.8× | −214.9% | 0.0× | n/a |
| Foresee Pharmaceuticals Co., Ltd. · TPEX:6576 | US$319.8M | US$303.4M | 469× | 21.2× | n/a | 8.3× | 4.8% | 0.3× | n/a |
| GI Innovation, Inc. · KRX:358570 | US$317.8M | US$288.6M | n/a | n/a | n/a | 4.4× | n/a | 0.0× | n/a |
| Atea Pharmaceuticals, Inc. · NASDAQ:AVIR | US$317.6M | US$126.6M | n/a | n/a | n/a | 1.8× | n/a | 0.0× | 0.86 |
| Median of the others | US$326.0M | US$246.6M | 469× | 1,151× | 3.4× | 2.5× | −214.9% | 0.1× | 1.16 |
Forecasts
11 strong buy · 1 buy · 3 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 26.15 USD · Analysts' mean
- EPS, year to Dec 2026
- -4.54 · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Christopher Kroeger | Chief Executive Officer, Founder, Board Member |
| Jonathan Gillis | Interim Chief Financial Officer, Chief Administrative and Accounting Officer |
| Kris Hanson | General Counsel |
| Anatol Kreitzer | Chief Discovery Officer |
| Erin Pennock Foff | Chief Medical Officer |
| James Lillie | Chief Scientific Officer |
| Karl Deisseroth | Founder, Scientific Advisory Board |
| Robert Malenka | Founder, Board of Directors, Scientific Advisory Board |
Board
| Director | Role |
|---|---|
| Christopher Kroeger | Chief Executive Officer, Founder, Board Member |
| George Pavlov | Board Member |
| Maria Walker | Chair of the Audit Committee |
| Martin Babler | Member of the Audit Committee |
| Nanna Lüneborg | General Partner at Forbion, Board Member |
| Robert Malenka | Founder, Board of Directors, Scientific Advisory Board |
| Tim Garnett | Chair of the Compensation Committee |
| Troy Cox | Chair of the Nominating and Corporate Governance Committee |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · Before open | −4.8% |
| Q2 2026 | Aug 13, 2026 · After close | +1.5% |
| Q1 2026 | May 15, 2026 | −9.5% |
| Q4 2025 | Mar 26, 2026 · Before open | +6.0% |
| Q3 2025 | Dec 4, 2025 · Before open | +8.4% |
| Q2 2025 | Sep 19, 2025 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 28 slides | Nov 16, 2026 |
| Investor Presentation (August 2026) | Investor deck | 28 slides | Aug 13, 2026 |
| Technical Presentation (July 2026) | Technical | 27 slides | Jul 27, 2026 |
| Technical Presentation (June 2026) | Technical | 21 slides | Jun 22, 2026 |
| Investor Presentation (May 2026) | Investor deck | 34 slides | May 14, 2026 |
| Investor Presentation (March 2026) | Investor deck | 34 slides | Mar 26, 2026 |
| Investor Presentation (January 2026) | Investor deck | 34 slides | Jan 9, 2026 |
| Investor Presentation (December 2025) | Investor deck | 32 slides | Dec 4, 2025 |
Financings
| Raise | Date |
|---|---|
| Private placement of common stock and pre-funded warrants Announced: about US$150M · US$11.38 a share · Morgan Stanley +3 Dealers: Morgan Stanley, Jefferies, Leerink Partners, Stifel Use of proceeds: Advance ML-007C-MA, including the VISTA Phase 2 and ZEPHYR-2 Phase 3 studies, plus working capital and general corporate purposes | Aug 13, 2026 |
| Public offering of common stock Closed: US$17 a share · Morgan Stanley +3 Dealers: Morgan Stanley (co-lead), Jefferies (co-lead), Leerink Partners (co-lead), Stifel (co-lead) | Oct 29, 2025 |
| Private placement of common stock Closed: US$17 a share Buyers: Affiliates of Goldman Sachs & Co. LLC (476,707 shares of common stock, including certain investment funds managed by Goldman Sachs & Co. LLC) | Oct 29, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$17.00 a share on Oct 26, 2025.
- Price
- US$17.00 a share
- Shares offered
- 14,750,000 shares of common stock
- Offering size
- US$250.8 million
- Underwriters' option
- Up to 2,212,500 more shares
- Listing
- MPLT on the Nasdaq Global Select Market
- Underwriters
- MORGAN STANLEY, JEFFERIES, LEERINK PARTNERS, STIFEL · In the order on the cover
- Shares delivered
- On or about Oct 28, 2025
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 8, 2024 |
| Filed publicly | Sep 19, 2025 |
| Amended once | Oct 6, 2025 |
| Shares registered with an exchange | Oct 24, 2025 |
| Final prospectus, with the price | Oct 27, 2025 |
Filings
| Filing | Filed |
|---|---|
| 424B3 · Prospectus | Oct 27, 2025 |
| FWP · Free writing prospectus | Oct 27, 2025 |
| CERT · Exchange's certificate of listing | Oct 24, 2025 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 24, 2025 |
| FWP · Free writing prospectus | Oct 6, 2025 |
| S-1/A · Registration statement, amended | Oct 6, 2025 |
| S-1 · Registration statement | Sep 19, 2025 |
| DRSLTR · Letter to the SEC with a draft | Aug 22, 2025 |
| DRS/A · Draft registration statement, amended | Aug 22, 2025 |
| UPLOAD · Letter from the SEC | Aug 12, 2025 |
All 18 filings
| Filing | Filed |
|---|---|
| DRS/A · Draft registration statement, amended | Jul 30, 2025 |
| DRSLTR · Letter to the SEC with a draft | May 10, 2024 |
| DRS/A · Draft registration statement, amended | May 10, 2024 |
| UPLOAD · Letter from the SEC | Apr 24, 2024 |
| DRSLTR · Letter to the SEC with a draft | Apr 12, 2024 |
| DRS/A · Draft registration statement, amended | Apr 12, 2024 |
| UPLOAD · Letter from the SEC | Apr 4, 2024 |
| DRS · Draft registration statement | Mar 8, 2024 |
Open IPO · From the cover of the final prospectus (424B3) filed Oct 27, 2025
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 0 | |||
| Cost of revenue | 578.0K | 701.0K | 556.0K | 574.0K |
| Gross profit | -578.0K | -701.0K | -556.0K | -574.0K |
| Research and development | 138.3M | 68.5M | 49.1M | 26.6M |
| Selling, general and administrative | 30.7M | 14.4M | 7.61M | 4.10M |
| Operating income | -169.1M | -82.9M | -57.3M | -31.2M |
| Depreciation and amortization | 578.0K | 701.0K | 556.0K | 574.0K |
| EBITDA | -168.5M | -82.2M | -56.7M | -30.7M |
| Income before tax | -161.2M | -77.6M | -55.7M | -30.0M |
| Net income | -161.2M | -77.6M | -55.7M | -30.0M |
| Earnings per share, basic | -18.56 | -105.38 | -1.34 | -0.72 |
| Earnings per share, diluted | -18.56 | -105.38 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 46.7M | 38.3M | 79.8M | 27.7M |
| Short-term investments | 258.4M | 70.5M | ||
| Current assets | 324.7M | 114.6M | 83.6M | 32.0M |
| Property, plant and equipment | 1.09M | 1.21M | ||
| Total assets | 479.5M | 136.9M | 91.4M | 39.4M |
| Accounts payable | 3.29M | 1.91M | 3.25M | 3.60M |
| Current liabilities | 16.2M | 15.9M | 14.7M | 12.6M |
| Total debt | 5.80M | 6.58M | 5.92M | 6.27M |
| Total liabilities | 21.1M | 21.7M | 20.1M | 18.5M |
| Shareholders' equity | 458.4M | -193.6M | 71.3M | 20.9M |
| Shares outstanding | 44.0M | 761.3K | 41.4M | 41.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -138.1M | -78.8M | -52.0M | -26.6M |
| Capital spending | -473.0K | -770.0K | -462.0K | -746.0K |
| Free cash flow | -138.6M | -79.6M | -52.5M | -27.3M |
| Cash from investing | -323.2M | -80.8M | -462.0K | -746.0K |
| Cash from financing | 469.8M | 118.1M | 104.6M | 33.2M |
| Change in cash | 8.48M | -41.5M | 52.1M | 27.7M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| EFFECT · Notice that a registration is effective | Nov 18, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 16, 2026 | Material contract | SEC |
| S-3 · Registration statement | Nov 16, 2026 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Nov 16, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 16, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 15, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Sep 24, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Sep 23, 2026 | Offer document | SEC |
| S-1/A · Registration statement, amended | Sep 18, 2026 | Offer document | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 16, 2026 | Other filings | SEC |
| S-1 · Registration statement | Sep 9, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 20, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 18, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 3, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 3, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 31, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 30, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 28, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 27, 2026 | Current report | SEC |
| 4 · Change in ownership | Jul 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 17, 2026 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Jul 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 25, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 25, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 24, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 22, 2026 | Current report | SEC |
| 8-K · Current report | Jun 18, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 29, 2026 | Management or board change | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 27, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 15, 2026 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Apr 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 15, 2026 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Apr 15, 2026 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Apr 15, 2026 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Apr 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 15, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 26, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 26, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 13, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 30, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 28, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 9, 2026 | Results | SEC |
| 10-Q · Quarterly report | Dec 4, 2025 | Quarterly report | SEC |
| 8-K · Current report | Dec 4, 2025 | Results | SEC |
| SCHEDULE 13D · Big-stake notice | Nov 20, 2025 | Big-stake notice | SEC |
| 3/A · Initial statement of ownership, amended | Nov 18, 2025 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Nov 4, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 29, 2025 | Financing | SEC |
| 4 · Change in ownership | Oct 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 27, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 27, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 27, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 27, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 27, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 27, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 27, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 27, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 27, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 27, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 27, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 27, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 27, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 27, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 27, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Oct 27, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Oct 27, 2025 | Offer document | SEC |
| FWP · Free writing prospectus | Oct 27, 2025 | Offer document | SEC |
| CERT · Exchange's certificate of listing | Oct 24, 2025 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Oct 24, 2025 | Other filings | SEC |
| FWP · Free writing prospectus | Oct 6, 2025 | Offer document | SEC |
| S-1/A · Registration statement, amended | Oct 6, 2025 | Offer document | SEC |
| S-1 · Registration statement | Sep 19, 2025 | Offer document | SEC |
| DRSLTR · Letter to the SEC with a draft | Aug 22, 2025 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Aug 22, 2025 | Offer document | SEC |
This page holds 200 of 217 filings. Open Filings
Cap table
Built by 6ix from MapLight Therapeutics, Inc.’s releases · as of Aug 13, 2026
- Common shares
- 52,848,208
- Fully diluted
- 52,848,208
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 52,848,208 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 52,848,208 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Martin Babler Other companies: Alumis Inc. (President, CEO and Chairman, Director · Since at least Jun 27, 2024); 89bio Inc (Director · Since at least Apr 13, 2024); Prelude Therapeutics Incorporated (Director · Since at least Jun 17, 2022); Neurogene Inc. (Director · May 12, 2022 – Jun 8, 2023 · Past) | Member of the Audit Committee · Since at least Jun 23, 2026 |
| Troy Cox Other companies: Standard BioTools Inc. (Director · Since at least Jun 18, 2026); Sophia Genetics SA (Board Member and Lead Independent Director · Since at least Jun 10, 2026) | Chair of the Nominating and Corporate Governance Committee · Since at least Jun 23, 2026 |
| Kristopher Hanson Other companies: PhaseBio Pharmaceuticals Inc (SVP and General Counsel · Nov 20, 2020 – May 20, 2022 · Past) | General Counsel · Since at least Oct 25, 2025 |
| Maria Walker Other companies: Five9, Inc. (Director · Since at least May 20, 2026) | Director · Since at least Jun 23, 2026 |
| Anatol Kreitzer | Chief Discovery Officer · Since at least Oct 25, 2025 |
| Christopher Kroeger | Chief Executive Officer, Director · Since at least Apr 15, 2026 |
| Erin Pennock Foff | Chief Medical Officer · Since at least Apr 15, 2026 |
| George Pavlov | Board Member · Since at least Jun 25, 2026 |
| James D Trenkle | Director · Since at least Oct 25, 2025 |
| James Lillie | Chief Scientific Officer · Since at least Oct 25, 2025 |
All 17 people
| Person | Seat |
|---|---|
| Jonathan Gillis | Interim Chief Financial Officer, Chief Administrative and Accounting Officer · Since at least Oct 16, 2026 |
| Karl Deisseroth | Founder, Scientific Advisory Board · Since at least Oct 6, 2026 |
| Kris Hanson | General Counsel · Since at least Oct 16, 2026 |
| Nanna Lüneborg | Director · Since at least Jun 23, 2026 |
| Robert Malenka | Founder, Board of Directors, Scientific Advisory Board · Since at least Oct 25, 2025 |
| Timothy Garnett | Director · Since at least Oct 25, 2025 |
| Vishwas Setia | Chief Financial Officer · Since at least Oct 25, 2025 |
Log in to ask 6ix AI your own questions about MapLight Therapeutics, Inc.